@article{10.11648/j.ijg.20230702.14,
  author = {Daniel Frederick Cruz Ulep and Adolf Lim-Teodoro and Emmanuel Monsayac},
  title = {Clinical Outcome of Patients with COVID Transaminitis Given Essential Phospholipids in a Tertiary Medical Center: A Retrospective Cohort Study},
  journal = {International Journal of Gastroenterology},
  volume = {7},
  number = {2},
  pages = {57-63},
  doi = {10.11648/j.ijg.20230702.14},
  url = {https://doi.org/10.11648/j.ijg.20230702.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijg.20230702.14},
  abstract = {Background: The COVID-19 pandemic has been a global public health challenge since the initial emergence of the novel coronavirus. COVID-19 infections can cause multi-systemic effects, including gastrointestinal symptoms such as abdominal pain, loose bowel movement, and increased liver enzymes, leading to transaminitis. The use of essential phospholipids, with its anti-inflammatory, antioxidant, antifibrinogenic, antiapoptotic, membrane-protective, and lipid-regulating effects, may be a viable treatment option for COVID-19-induced transaminitis. Methods: This retrospective cohort study aims to evaluate the clinical outcomes of administering essential phospholipids to adult Filipino patients with COVID-19 Transaminitis admitted in a tertiary medical center from July 2021 to February 2022. A total of 238 COVID-19 patients admitted met the inclusion criteria. The primary treatment arm consists of 156 patients who received essential phospholipids during admission, while the control arm consists of the remaining 82 patients who did not receive essential phospholipids. The study's statistical analysis utilized Wilcoxon Signed Rank Test, Mann-Whitney U Test, and Chi-square test. The computed minimum sample size is 109 based on a confidence value of 95%, a margin of error of 5, 50% population proportion, and a population size of 150. Results: The study shows that the prevalence of COVID-19 Transaminitis is 70%. There is also a significant decrease from baseline to repeat serum AST and ALT levels for patients who took essential phospholipids. Although not statistically significant, there is a trend toward a decrease in mortality rate from those patients who took essential phospholipids compared to those who did not (16% vs. 24% respectively). There was also higher mortality rate for those patients with COVID-19 transaminitis (21%), from those who did not have COVID-19 transaminitis (16%), however, the study did not reach the level of significance. There is a significant difference in the number of COVID-19 critical patients with transaminitis compared to those who did not have transaminitis (51% vs 33%). Conclusion: The prevalence of transaminitis in COVID-19 infection is high. essential phospholipids may hold promise as an effective treatment option for COVID-19 transaminitis. The presence of transaminitis in COVID-19 patients appears to have a significant impact on the severity of the disease or the course of treatment.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Clinical Outcome of Patients with COVID Transaminitis Given Essential Phospholipids in a Tertiary Medical Center: A Retrospective Cohort Study
AU  - Daniel Frederick Cruz Ulep
AU  - Adolf Lim-Teodoro
AU  - Emmanuel Monsayac
Y1  - 2023/09/06
PY  - 2023
N1  - https://doi.org/10.11648/j.ijg.20230702.14
DO  - 10.11648/j.ijg.20230702.14
T2  - International Journal of Gastroenterology
JF  - International Journal of Gastroenterology
JO  - International Journal of Gastroenterology
SP  - 57
EP  - 63
PB  - Science Publishing Group
SN  - 2640-169X
UR  - https://doi.org/10.11648/j.ijg.20230702.14
AB  - Background: The COVID-19 pandemic has been a global public health challenge since the initial emergence of the novel coronavirus. COVID-19 infections can cause multi-systemic effects, including gastrointestinal symptoms such as abdominal pain, loose bowel movement, and increased liver enzymes, leading to transaminitis. The use of essential phospholipids, with its anti-inflammatory, antioxidant, antifibrinogenic, antiapoptotic, membrane-protective, and lipid-regulating effects, may be a viable treatment option for COVID-19-induced transaminitis. Methods: This retrospective cohort study aims to evaluate the clinical outcomes of administering essential phospholipids to adult Filipino patients with COVID-19 Transaminitis admitted in a tertiary medical center from July 2021 to February 2022. A total of 238 COVID-19 patients admitted met the inclusion criteria. The primary treatment arm consists of 156 patients who received essential phospholipids during admission, while the control arm consists of the remaining 82 patients who did not receive essential phospholipids. The study's statistical analysis utilized Wilcoxon Signed Rank Test, Mann-Whitney U Test, and Chi-square test. The computed minimum sample size is 109 based on a confidence value of 95%, a margin of error of 5, 50% population proportion, and a population size of 150. Results: The study shows that the prevalence of COVID-19 Transaminitis is 70%. There is also a significant decrease from baseline to repeat serum AST and ALT levels for patients who took essential phospholipids. Although not statistically significant, there is a trend toward a decrease in mortality rate from those patients who took essential phospholipids compared to those who did not (16% vs. 24% respectively). There was also higher mortality rate for those patients with COVID-19 transaminitis (21%), from those who did not have COVID-19 transaminitis (16%), however, the study did not reach the level of significance. There is a significant difference in the number of COVID-19 critical patients with transaminitis compared to those who did not have transaminitis (51% vs 33%). Conclusion: The prevalence of transaminitis in COVID-19 infection is high. essential phospholipids may hold promise as an effective treatment option for COVID-19 transaminitis. The presence of transaminitis in COVID-19 patients appears to have a significant impact on the severity of the disease or the course of treatment.
VL  - 7
IS  - 2
ER  - 

Copy | Download